and the annual EBITDA is expected to be 2.6 billion euros - morpholine

and the annual EBITDA is expected to be 2.6 billion euros

Evonik’s sales revenue in the second quarter of 2022 increased by 31%, and the annual EBITDA is expected to be 2.6 billion euros2022-08-10